|
Study design
|
|
| Systematic reviews ± meta-analyses |
3 |
| Randomised controlled trials |
23 |
| Non-randomised controlled trials |
137 |
| Non-randomised clinical studies |
43 |
| Prospective cohort studies |
1 |
| Case series |
2 |
|
Setting of conduct
|
|
| Community or primary care |
5 |
| Outpatient department or hospital clinic |
127 |
| Other |
3 |
| Not stated |
74 |
|
UN inequality-adjusted Human Development Index 2010
|
|
| Very high |
186 |
| High |
16 |
| Medium |
3 |
| Low |
0 |
| No data |
4 |
|
Study population (aetiology of immunocompromise)
*
|
|
| Human immunodeficiency virus (HIV) infection |
58 |
| Cancers |
56 |
| Transpla nt recipients |
52 |
| Autoimmune diseases receiving immunosuppressive therapy |
34 |
| Respiratory diseases receiving immunosuppressive therapy |
5 |
| Other |
7 |
